These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 19337536)

  • 1. Cardiometabolic risk in psoriasis: differential effects of biologic agents.
    Kaplan MJ
    Vasc Health Risk Manag; 2008; 4(6):1229-35. PubMed ID: 19337536
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chronic inflammation, cardiometabolic diseases and effects of treatment: Psoriasis as a human model.
    Aksentijevich M; Lateef SS; Anzenberg P; Dey AK; Mehta NN
    Trends Cardiovasc Med; 2020 Nov; 30(8):472-478. PubMed ID: 31837960
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The concept of psoriasis as a systemic inflammation: implications for disease management.
    Reich K
    J Eur Acad Dermatol Venereol; 2012 Mar; 26 Suppl 2():3-11. PubMed ID: 22356630
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Accumulating evidence for the association and shared pathogenic mechanisms between psoriasis and cardiovascular-related comorbidities.
    Shlyankevich J; Mehta NN; Krueger JG; Strober B; Gudjonsson JE; Qureshi AA; Tebbey PW; Kimball AB
    Am J Med; 2014 Dec; 127(12):1148-53. PubMed ID: 25149424
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of regulatory T cells and anti-inflammatory cytokines in psoriasis.
    Owczarczyk-Saczonek A; Czerwińska J; Placek W
    Acta Dermatovenerol Alp Pannonica Adriat; 2018 Mar; 27(1):17-23. PubMed ID: 29589640
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Effect of Tildrakizumab on Cardiometabolic Risk Factors in Psoriasis by Metabolic Syndrome Status: Post Hoc Analysis of Two Phase 3 Trials (ReSURFACE 1 and ReSURFACE 2).
    Menter MA; Mehta NN; Lebwohl MG; Gottlieb AB; Mendelsohn AM; Rozzo SJ; Leonardi C
    J Drugs Dermatol; 2020 Aug; 19(8):703-708. PubMed ID: 32845115
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Investigating the Link between Psoriasis and Cardiovascular Disease: Current Evidence, Therapeutic Implications and Perspectives.
    Kapniari E; Papadimitriou P; Dalamaga M; Makavos G; Piaserico S; Egeberg A; Ikonomidis I; Papadavid E
    Curr Vasc Pharmacol; 2020; 18(6):592-609. PubMed ID: 32445456
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Psoriasis and atherothrombotic disease].
    Ahlehoff O; Gislason GH; Skov L; Hansen PR
    Ugeskr Laeger; 2010 Jun; 172(26):1983-6. PubMed ID: 20654288
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Double trouble: psoriasis and cardiometabolic disorders.
    Mahyoodeen NG; Crowther NJ; Tikly M
    Cardiovasc J Afr; 2018 May/Jun 23; 29(3):189-194. PubMed ID: 29293257
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathogenic mechanisms shared between psoriasis and cardiovascular disease.
    Ghazizadeh R; Shimizu H; Tosa M; Ghazizadeh M
    Int J Med Sci; 2010 Aug; 7(5):284-9. PubMed ID: 20827428
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolic syndrome in patients with psoriatic disease.
    Gelfand JM; Yeung H
    J Rheumatol Suppl; 2012 Jul; 89():24-8. PubMed ID: 22751586
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thrombosis in Psoriasis: Cutaneous Cytokine Production as a Potential Driving Force of Haemostatic Dysregulation and Subsequent Cardiovascular Risk.
    Visser MJE; Tarr G; Pretorius E
    Front Immunol; 2021; 12():688861. PubMed ID: 34335591
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potential Immunological Links Between Psoriasis and Cardiovascular Disease.
    Sajja AP; Joshi AA; Teague HL; Dey AK; Mehta NN
    Front Immunol; 2018; 9():1234. PubMed ID: 29910818
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Psoriasis and Cardiometabolic Diseases: Shared Genetic and Molecular Pathways.
    Piaserico S; Orlando G; Messina F
    Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012327
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The association of psoriasis and hypertension: focusing on anti-inflammatory therapies and immunological mechanisms.
    Hu MY; Yang Q; Zheng J
    Clin Exp Dermatol; 2020 Oct; 45(7):836-840. PubMed ID: 32789979
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiovascular Risk in Patients With Psoriasis: JACC Review Topic of the Week.
    Garshick MS; Ward NL; Krueger JG; Berger JS
    J Am Coll Cardiol; 2021 Apr; 77(13):1670-1680. PubMed ID: 33795041
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Underdiagnosis and undertreatment of cardiovascular risk factors in patients with moderate to severe psoriasis.
    Kimball AB; Szapary P; Mrowietz U; Reich K; Langley RG; You Y; Hsu MC; Yeilding N; Rader DJ; Mehta NN
    J Am Acad Dermatol; 2012 Jul; 67(1):76-85. PubMed ID: 22018756
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ischemic cardiovascular involvement in psoriasis: a systematic review.
    Mosca S; Gargiulo P; Balato N; Di Costanzo L; Parente A; Paolillo S; Ayala F; Trimarco B; Crea F; Perrone-Filardi P
    Int J Cardiol; 2015 Jan; 178():191-9. PubMed ID: 25464252
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Psoriasis and metabolic syndrome: implications for the management and treatment of psoriasis.
    Wu JJ; Kavanaugh A; Lebwohl MG; Gniadecki R; Merola JF
    J Eur Acad Dermatol Venereol; 2022 Jun; 36(6):797-806. PubMed ID: 35238067
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic markers for cardiovascular disease in psoriasis: the missing piece.
    Torres T; Chiricozzi A; Chimenti S; Saraceno R
    Mol Diagn Ther; 2014 Feb; 18(1):93-5. PubMed ID: 24078347
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.